Trial Profile
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease; Tauopathies
- Focus Diagnostic use
- Sponsors Molecular NeuroImaging
- 27 Mar 2019 According to a Life Molecular Imaging, Piramal imaging changed its name to Life Molecular Imaging.
- 15 Dec 2016 Status changed from recruiting to completed.
- 26 Aug 2015 New trial record